Dual Gene Therapy Has Beneficial Effects On Blood Biomarkers And Muscle Composition02 March 2017
In April 2016 BioViva USA Inc. published a press release stating that Elizabeth Parrish, CEO, had experienced telomere lengthening in her leukocytes, as a result of an injection of two experimental therapies. These consisted of a myostatin inhibitor to protect against loss of muscle mass with age, and a telomerase inducer to battle stem cell depletion responsible for diverse age-related diseases and infirmities. The experiment was designed to establish the first human safety data regarding telomerase induction, but subsequent testing by SpectraCell Laboratories indicated that her leukocyte telomeres had lengthened by approximately 20 years, from 6.71kb to 7.33kb. Further data will be released later this year.
Further examination of Parrish’s data prior to the therapy and following the therapy has revealed additional positive changes. MRI scans taken before and after depict a slight increase in muscle size in conjunction with a noticeable reduction in muscle fat content. An overaccumulation of intramuscular fat, also known as ‘marbling’, is associated with increased insulin resistance (1), and as such an appropriate reduction may be linked to beneficial metabolic changes in addition to improved musculature. The aforementioned patient’s total body weight has not decreased during this period, and as such weight loss is not a confounding variable. More importantly, this apparent muscle growth was achieved without any exercise regime. We therefore predict that results may be more striking in more physically active individuals. The muscle growth achieved post-therapy corresponds with observed improvements in patients with Becker’s Muscular Dystrophy (2), after receipt of myostatin inhibition gene therapy.
Bernardes de Jesus et al., 2012 (3), noted that a significant reduction in fasting glucose was apparent in mice following AAV mediated telomerase induction. The subject’s fasting glucose has declined from previous measurements of 94 mg/dL and 86 mg/dL, to a fasting glucose level of 71 mg/dL by August 2016, as measured by Quest Diagnostics. Repeated testing will confirm the implied increase in insulin sensitivity. Previous research has also indicated that telomerase deficiency impairs glucose metabolism and insulin secretion in telomerase deficient mice (4), which may explain an apparent improvement in metabolic markers.
In accordance with an improvement in metabolic health, triglyceride levels also declined from 140 mg/dL in 2015 to 36 mg/dL in February 2016, subsequently rising to 80 and 84 mg/dL in August 2016. While there has been an increase in blood triglyceride content following the February reading, it is still measurably lower than before treatment. Both decreases in fasting glucose and triglycerides can be potentially explained by prior studies of telomerase and myostatin. Raised myostatin mRNA seen in type 2 diabetes patients is associated with impaired insulin sensitivity, raising triglyceride levels and low-grade chronic inflammation (5). Myostatin inhibition in mice has also been shown to reduce triglyceride levels and improve insulin sensitivity (6).
In addition to these apparent benefits, blood analysis has revealed further insights into the effects of the complementary therapies. C-Reactive Protein, a potent marker of systemic inflammation, was notably decreased from 1.6 mg/dL to <0.2 mg/dL in the months following administration of both gene therapies. This could perhaps be explained through a lengthening of critically short telomeres, averting and ameliorating senescence, in addition to the therapy’s expected result of preventing oxidative and nuclear DNA damage.
No negative effects have been reported. Blood analysis has revealed no detrimental effects thus far, providing tentative evidence of safety in the first human test of BioViva’s dual gene therapy strategy.
This data first and foremost implies that these therapies are likely safe in humans, which was our primary concern. Additionally, it also reveals potentially beneficial metabolic changes that may conform to previous research findings. These trends may become more significant following further confirmation as we continuously monitor my biomarkers, but we are certainly encouraged by the results we have seen so far.
**Elizabeth Parrish, CEO**
- Phillips, D. I. W., et al. “Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects.” Metabolism 45.8 (1996): 947-950.
- Mendell, Jerry R., et al. “A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.” Molecular Therapy 23.1 (2015): 192-201.
- de Jesus, Bruno Bernardes, et al. “Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer.” EMBO molecular medicine 4.8 (2012): 691-704.
- Kuhlow, Doreen, et al. “Telomerase deficiency impairs glucose metabolism and insulin secretion.” Aging (Albany NY) 2.10 (2010): 650-8.
- Brandt, Claus, et al. “Plasma and muscle myostatin in relation to type 2 diabetes.” PLoS One 7.5 (2012): e37236
- Guo, Tingqing, et al. “Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy.” Diabetes 61.10 (2012): 2414-2423.
About: BioViva USA, Inc. is a to-clinic gene and cell therapeutics company incorporated in Delaware. BioViva utilizes intramural and extramural peer-reviewed research in order to create marketable therapies for treating age-related diseases and infirmities ‒ including Parkinson’s, Alzheimer’s, heart-disease, cancer, sarcopenia and kidney failure ‒ at the level of the genome. For more information visit: www.Bioviva-Science.com